Literature DB >> 9094204

Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine.

M R Kilbourn1, L C Lee, M J Heeg, D M Jewett.   

Abstract

Chiral column liquid chromatography and enantiospecific enzymatic hydrolysis were utilized to separate the enantiomers of alpha- and beta-dihydrotetrabenazine and alpha-9-O-desmethyldihydrotetrabenazine, three benzo[a]quinolizines derived from the amine-depleting drug tetrabenazine. An X-ray crystal structure analysis of (-)-alpha-9-O-desmethyldihydrotetrabenazine gave an absolute structure of that compound as the 2S, 3S, 11bS isomer. Therefore, (-)-alpha-dihydrotetrabenazine also has the 2S, 3S, 11bS absolute configuration. (+)-alpha-Dihydrotetrabenazine, the single biologically active isomer from the metabolic reduction of tetrabenazine, thus has the absolute configuration of 2R, 3R, 11bR. For further in vitro and in vivo studies of the vesicular monoamine transporter, it is now possible to use the single enantiomer of radiolabeled alpha-dihydrotetrabenazine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094204     DOI: 10.1002/(SICI)1520-636X(1997)9:1<59::AID-CHIR11>3.0.CO;2-P

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  9 in total

1.  Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

2.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors:  Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

3.  Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.

Authors:  Michael R Kilbourn; Brian Hockley; Lihsueh Lee; Catherine Hou; Rajesh Goswami; Datta E Ponde; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

Review 4.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

5.  Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.

Authors:  Zhangyu Yao; Xueying Wei; Xiaoming Wu; Jonathan L Katz; Theresa Kopajtic; Nigel H Greig; Hongbin Sun
Journal:  Eur J Med Chem       Date:  2011-02-23       Impact factor: 6.514

6.  In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine.

Authors:  Hank F Kung; Brian P Lieberman; Zhi-Ping Zhuang; Shunichi Oya; Mei-Ping Kung; Seok Rye Choi; Karl Poessl; Eric Blankemeyer; Catherine Hou; Daniel Skovronsky; Michael Kilbourn
Journal:  Nucl Med Biol       Date:  2008-11       Impact factor: 2.408

7.  Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.

Authors:  Fabiola Souza; Norman Simpson; Anthony Raffo; Chitra Saxena; Antonella Maffei; Mark Hardy; Michael Kilbourn; Robin Goland; Rudolph Leibel; J John Mann; Ronald Van Heertum; Paul E Harris
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

8.  Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.

Authors:  Heather Skor; Evan B Smith; Gordon Loewen; Christopher F O'Brien; Dimitri E Grigoriadis; Haig Bozigian
Journal:  Drugs R D       Date:  2017-09

Review 9.  Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity.

Authors:  Seung-Mann Paek
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.